Analysis Group Researchers to Present at ISPE 2024
Event:40th International Society for Pharmacoepidemiology (ISPE) Annual Meeting
Dates:
August 24–28, 2024
Host:
International Society for Pharmacoepidemiology (ISPE)
Location:
Berlin, Germany
Analysis Group, a global leader in drug safety epidemiology and regulatory real-world evidence (RWE), will present two podium presentations and five research posters at the 40th annual meeting of the International Society for Pharmacoepidemiology (ISPE).
Vice President Marianne Cunnington is a coauthor of two podium presentations at the meeting:
Monday, August 26, 1:30 p.m. CEST, Convention Hall I D
- Applying the self-controlled case series to analyze safety endpoints in single-arm, open label extension studies: A case study of Belimumab for the treatment of systemic lupus erythematosus and risk of infection
Wednesday, August 28, 8:45 a.m. CEST, Room XV
- Impact of data source diversity on the distribution of key variables in pregnancy cohorts based on the ConcePTION pregnancy algorithm leveraging a random forest imputation model
Additionally, researchers from Analysis Group – including Managing Principals Mei Sheng Duh and Maral DerSarkissian; Vice Presidents Rose Chang, Marianne Cunnington, and Fan Mu; and Managers Catherine Nguyen and Erin Cook – will present five posters at the meeting on the following topics:
Poster Session A: Monday, August 26, 8:00 a.m.–6:00 p.m. CEST
- Poster No. 158: Comparative Effectiveness of ARB and ACEi for Cardiovascular Outcomes and Risk of Angioedema by Ethnicity: an Analysis in the UK Clinical Practice Research Datalink with Emulation of a Reference Trial (ONTARGET)
- Poster No. 108: Impact of Treatment of COVID-19 with Sotrovimab on Post-Acute COVID-19 Syndrome: An Analysis of National COVID Cohort Collaborative (N3C) Data
- Poster No. 070: NALIRIFOX versus FOLFOX as first-line treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC): Real-world comparative overall (OS) survival analysis
Poster Session B: Tuesday, August 27, 8:00 a.m.–6:00 p.m. CEST
- Poster No. 342: Final Results from Post-Emergency Use Authorization (EUA) Active Safety Surveillance Study among Individuals in the Veterans Affairs Health System Receiving Pfizer-BioNTech Coronavirus Disease 2019 (COVID-19) Vaccine
Poster Session C: Wednesday, August 28, 8:00 a.m.–1:30 p.m. CEST
- Poster No. 305: High Misclassification of Glycogen Storage Disease Type 1a in a US Electronic Medical Records Database – Insights from a Physician Note Review
Further details on the podium presentations and posters are available in our 2024 ISPE Presentation Guide. Analysis Group is a proud gold sponsor of this meeting.